Anebulo Pharmaceuticals (ANEB) - חוב לטווח ארוך להון

Anebulo Pharmaceuticals is developing treatments for cannabis intoxication while expanding its therapy to other addictions. The trajectory of the long-term financial leverage ratio on the GURU.Markets chart, where the current metric is 0.00, highlights the defensive qualities of the business against GDP downturns. Meanwhile, the company minimizes vendor risks by delegating early-stage research to external laboratories while maintaining full control over patents.

Anebulo Pharmaceuticals focuses on high-tech R&D development of the Anebound antidote and brain receptor modulators. This metric assesses the share of liabilities with a maturity of more than one year relative to equity. It is critical for investors to understand the extent to which borrowed funds finance scientific potential without the risk of excessive debt load. An optimal balance avoids excessive interest payments while capturing the benefits of low-cost loans. Financial leverage based on long-term debt clearly demonstrates this stability.